On May 15, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy.

Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) is a type of CAR T cell therapy. CAR T cell therapy provides engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens present on the surface of lymphoma cells. T cells are removed from patients and genetically modified to produce CARs. The genetically engineered CAR T cells are grown in the laboratory until they number in the billions and are then infused back into the patient.

“Patients with relapsed or refractory follicular lymphoma require options that are effective and allow them to fully participate in the share decision making process,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “We are thrilled to see how this approval will benefit many patients and provide hope for lasting remission.”

For more information on the FDA approval of lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.), visit the FDA’s website.